Skip to the page

Data / Drug companies / Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories, LLC: 71 products in the FDA NDC directory, labeler code 24979

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Upsher-Smith Laboratories, LLC (labeler code 24979) lists 71 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 71 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 27, 2026.

The request: Watch Upsher-Smith Laboratories, LLC (FDA labeler code 24979): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
24979
Products in commercial distribution
71
Packages
116
Finished drugs by generic name
25
Prescription products
71
Over the counter products
0
Controlled substance products
Schedule III 1
Flagged as original packager
63 of 63 products that carry the flag
Started marketing in the last 12 months
4
Products with a marketing end date set
1
Earliest marketing start
November 1, 2014
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)5577.5%
New drug applications (NDA)1318.3%
Authorized generics (NDA)34.2%

Products by type

TypeProductsShare
Prescription drugs71100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet, film coated1521.1%
Tablet1521.1%
Tablet, extended release1216.9%
Capsule, extended release1014.1%
Tablet, film coated, extended release912.7%
Capsule, delayed release45.6%
Capsule34.2%
Emulsion11.4%
Gel11.4%
Suspension11.4%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Cyclosporine24979-126EmulsionGeneric drugs (ANDA)March 27, 2026
Naprelan24979-251Tablet, film coated, extended releaseNew drug applications (NDA)December 31, 2025
Naprelan24979-250Tablet, film coated, extended releaseNew drug applications (NDA)December 31, 2025
Naprelan24979-249Tablet, film coated, extended releaseNew drug applications (NDA)December 31, 2025
Anastrozole24979-725TabletGeneric drugs (ANDA)March 21, 2025
Letrozole24979-726Tablet, film coatedGeneric drugs (ANDA)January 10, 2025
Potassium Chloride24979-230Tablet, extended releaseGeneric drugs (ANDA)October 28, 2024
Potassium Chloride24979-229Tablet, extended releaseGeneric drugs (ANDA)October 28, 2024
Tenormin24979-246TabletNew drug applications (NDA)August 1, 2024
Tenormin24979-245TabletNew drug applications (NDA)August 1, 2024
Tenormin24979-244TabletNew drug applications (NDA)August 1, 2024
Naproxen Sodium24979-253Tablet, film coated, extended releaseAuthorized generics (NDA)April 25, 2024
Naproxen Sodium24979-252Tablet, film coated, extended releaseAuthorized generics (NDA)April 25, 2024
Zestril24979-243TabletNew drug applications (NDA)April 25, 2024
Zestril24979-242TabletNew drug applications (NDA)April 25, 2024
Zestril24979-241TabletNew drug applications (NDA)April 25, 2024
Zestril24979-240TabletNew drug applications (NDA)April 25, 2024
Zestril24979-239TabletNew drug applications (NDA)April 25, 2024
Zestril24979-238TabletNew drug applications (NDA)April 25, 2024
Tadalafil24979-730Tablet, film coatedGeneric drugs (ANDA)April 7, 2024
Tadalafil24979-729Tablet, film coatedGeneric drugs (ANDA)April 7, 2024
Tadalafil24979-728Tablet, film coatedGeneric drugs (ANDA)April 7, 2024
Tadalafil24979-727Tablet, film coatedGeneric drugs (ANDA)April 7, 2024
Galantamine24979-724Tablet, film coatedGeneric drugs (ANDA)March 6, 2024
Galantamine24979-723Tablet, film coatedGeneric drugs (ANDA)March 6, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.